Menu
Search
|

Menu

Close
X

Eloxx Pharmaceuticals Inc ELOX.OQ (NASDAQ Stock Exchange Global Market)

8.24 USD
-0.96 (-10.43%)
As of Jul 19
Previous Close 9.20
Open 9.14
Volume 45,110
3m Avg Volume 27,141
Today’s High 9.14
Today’s Low 8.15
52 Week High 18.48
52 Week Low 8.15
Shares Outstanding (mil) 39.78
Market Capitalization (mil) 327.78
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-0.332
FY18
-1.449
FY17
-8.674
FY16
-8.278
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.52
Price to Sales (TTM)
vs sector
--
7.97
Price to Book (MRQ)
vs sector
8.60
4.45
Price to Cash Flow (TTM)
vs sector
--
24.33
Total Debt to Equity (MRQ)
vs sector
41.80
17.60
LT Debt to Equity (MRQ)
vs sector
38.94
12.58
Return on Investment (TTM)
vs sector
-163.01
12.69
Return on Equity (TTM)
vs sector
-210.74
17.17

EXECUTIVE LEADERSHIP

Robert Ward
Chairman of the Board, Chief Executive Officer, Since 2017
Salary: $452,885.00
Bonus: --
Gregory Weaver
Chief Financial Officer, Since 2017
Salary: $347,212.00
Bonus: --
Gregory Williams
Chief Operating Officer, Since 2018
Salary: $244,712.00
Bonus: $50,000.00
Neil Belloff
Executive Vice President, General Counsel, Corporate Secretary, Since 2018
Salary: --
Bonus: --
David Snow
Chief Business Officer, Since 2018
Salary: $197,460.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

950 Winter St
WALTHAM   MA   02451-1424

Phone: +1858.9090749

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing ribonucleic acid (RNA)-modulating drug candidates, which are designed to be eukaryotic ribosomal selective glycosides (ERSG). It is developing its drug candidates for treating rare and ultra-rare premature stop codon diseases. ELX-02 is its lead investigational drug product candidate. ELX-02 is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development for systemic administration for cystic fibrosis and cystinosis. Its preclinical candidate pool consists of a library of novel ERSG drug candidates identified based on read-through potential and cytoplasmic ribosomal selectivity.

SPONSORED STORIES